Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC SEC filings (Ticker: AUTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Autolus Therapeutics plc (Nasdaq: AUTL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a commercial-stage biopharmaceutical issuer. Autolus is incorporated in England and Wales, and its American Depositary Shares trade on The Nasdaq Global Select Market. As a foreign private issuer, Autolus files reports and current disclosures with the U.S. Securities and Exchange Commission, including Forms 20-F and 6-K, as well as current reports on Form 8-K related to material events.
In its filings, Autolus provides information on its business of developing, manufacturing and delivering next-generation programmed T cell therapies for cancer and autoimmune disease. Investors can use these documents to follow the commercial launch and performance of AUCATZYL® (obecabtagene autoleucel; obe-cel), a CD19-directed genetically modified autologous T cell immunotherapy indicated for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Filings often reference net product revenue, cost of sales, research and development expenses, and selling, general and administrative expenses, as well as cash, cash equivalents and marketable securities.
Current reports on Form 8-K for Autolus have included quarterly financial results, corporate updates, and governance changes such as the appointment of a principal accounting officer. These documents can also incorporate press releases that discuss clinical trial progress in programs like CATULUS, CARLYSLE, LUMINA, BOBCAT and ALARIC, and provide context on how Autolus is advancing its pipeline across hematological malignancies, solid tumors and autoimmune diseases.
On Stock Titan, SEC filings for AUTL are updated in near real time from EDGAR. Integrated AI-powered summaries help explain the key points in lengthy filings, including annual reports, interim financial updates and material event disclosures. Users can quickly scan for information on Autolus’ T cell programming technologies, AUCATZYL commercialization, manufacturing initiatives and capital position without reading every line of the underlying documents.
Autolus Therapeutics plc has changed its independent registered public accounting firm, dismissing Ernst & Young LLP (UK) and appointing Ernst & Young LLP (US) for the fiscal year ending December 31, 2026. The company states there were no disagreements with EY UK on accounting, disclosure, or audit matters and no reportable events, other than previously disclosed material weaknesses in internal control over financial reporting as of March 31, 2024. EY UK’s audit reports for the years ended December 31, 2025 and 2024 contained unmodified opinions, and EY UK has provided a letter to the SEC agreeing with the company’s description of the relationship.
Autolus Therapeutics plc filed a shelf registration on Form S-3 to offer, from time to time, up to $150,000,000 of ordinary shares, American Depositary Shares, debt securities and warrants. The prospectus is a general shelf: specific terms and any proceeds per offering will be set forth in prospectus supplements.
As context, the company reported 266,143,286 ordinary shares issued as of December 31, 2025. The prospectus states net proceeds will be used for clinical development, manufacturing, commercialization and general corporate purposes.
Autolus Therapeutics plc filed a registration statement on Form S-3 to register the resale by selling securityholders of up to 54,584,250 American Depositary Shares (ADSs). The amount comprises 51,318,944 ADSs previously issued and 3,265,306 ADSs issuable upon exercise of outstanding warrants. The company states the registration is being filed to satisfy contractual registration rights and that Autolus will receive no proceeds from sales by the selling securityholders. The ADSs trade on Nasdaq under the symbol AUTL; the prospectus cites a closing price of $1.47 per ADS on April 9, 2026. The filing describes customary resale methods, potential hedging and short-selling by purchasers or broker-dealers, indemnification arrangements and estimated registration expenses.
Autolus Therapeutics plc furnished an investor presentation focused on its acute lymphoblastic leukemia (ALL) business and its CD19 CAR-T therapy AUCATZYL/obe-cel. The slides highlight the high unmet need in adult and pediatric relapsed/refractory B-ALL and position CAR-T as a potential curative option, especially for patients ineligible for transplant.
The presentation reviews FELIX trial data, real‑world ROCCA registry experience, and pediatric CATULUS Phase Ib results, emphasizing high response rates, low rates of severe CRS/ICANS, and manageable manufacturing timelines. Autolus outlines plans to broaden AUCATZYL’s use across age groups, move obe‑cel into frontline consolidation, and support pediatric regulatory expansion through ongoing and planned studies.
Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on next‑generation programmed T cell therapies for cancer and autoimmune diseases. Its lead product, AUCATZYL (obe-cel), a CD19 CAR T therapy, is approved for adult relapsed or refractory B‑cell precursor acute lymphoblastic leukemia in the US, U.K. and EU.
Commercial launch and first US sales began in January 2025, with a U.K. launch through the National Health Service in January 2026. EU marketing authorization has been granted, but launch there is on hold while pricing and market feasibility are evaluated, and no EU sales are expected in 2026.
The company is expanding obe‑cel into pediatric B‑ALL and B‑NHL, additional B‑cell malignancies and autoimmune indications including systemic lupus erythematosus, lupus nephritis and progressive multiple sclerosis. Autolus operates a purpose‑built manufacturing facility in Stevenage, U.K., designed to support global CAR T supply using a semi‑automated, closed manufacturing platform.
Autolus Therapeutics reported fourth-quarter and full-year 2025 results that reflect its first commercial year for AUCATZYL. Net product revenue reached $23.3 million in Q4 2025 and $74.3 million for the full year, driving total 2025 revenue to $75.4 million including license revenue.
Autolus projects 2026 AUCATZYL net product revenue of $120 million to $135 million and expects to achieve a shift to positive gross margin in 2026 as volumes rise and manufacturing efficiency improves. Cost of sales were $96.4 million in 2025, research and development expenses $117.7 million, and selling, general and administrative expenses $131.9 million, resulting in a full-year net loss of $287.5 million.
Cash, cash equivalents and marketable securities totaled $300.7 million as of December 31, 2025, down from $588.0 million a year earlier, and the company expects this funding, together with anticipated AUCATZYL revenue, to support operations into Q4 2027. Autolus also highlighted advancing trials of obe-cel in pediatric B-ALL, lupus nephritis, progressive multiple sclerosis and systemic lupus erythematosus with multiple data readouts expected between year-end 2026 and 2028.
Autolus Therapeutics plc director Ryan Richardson reported an initial holding of a share option covering 80,000 underlying American Depositary Shares. The option has an exercise price of $1.41 per share and expires on December 1, 2035. It vests in 36 equal monthly installments starting on January 1, 2026, meaning the right to buy the shares builds gradually over three years. This filing does not reflect a new stock purchase or sale, but discloses an existing equity award position.
Autolus Therapeutics plc executive Cintia Piccina, U.S. CCO & Country General Manager, has filed a Form 3 reporting her existing equity awards. She holds share options over 500,000 American Depositary Shares at an exercise price of $1.49 expiring on October 8, 2035, and options over 148,000 ADS at $1.62 expiring on March 4, 2036. She also holds restricted share units covering 80,000 ADS that vest in four equal annual installments starting on September 1, 2026, and 33,000 RSUs vesting in four equal annual installments starting on March 4, 2027, with each RSU representing one ADS.
Autolus Therapeutics plc director Cynthia M. Butitta filed an initial ownership report showing her equity position in the company. She directly holds 10,000 American Depositary Shares, each convertible into one Ordinary Share, and a series of share options over additional American Depositary Shares with exercise prices ranging from $2.38 to $30.24 and expirations extending through 2035.
Autolus Therapeutics plc director Elisabeth Leiderman filed an initial Form 3 reporting her holdings of three option awards over American Depositary Shares. Each option covers 80,000 underlying ADS, with exercise prices of $5.5000, $3.4800 and $2.3200, expiring between December 20, 2033 and June 26, 2035. One grant is fully vested and exercisable, while the others vest in equal monthly installments beginning January 20, 2024 and July 26, 2025.